{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,7,1]],"date-time":"2026-07-01T21:45:08Z","timestamp":1782942308210,"version":"3.54.5"},"reference-count":13,"publisher":"Elsevier BV","issue":"7","license":[{"start":{"date-parts":[[2026,7,1]],"date-time":"2026-07-01T00:00:00Z","timestamp":1782864000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2026,7,1]],"date-time":"2026-07-01T00:00:00Z","timestamp":1782864000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"}],"content-domain":{"domain":["cell.com","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Molecular Therapy"],"published-print":{"date-parts":[[2026,7]]},"DOI":"10.1016\/j.ymthe.2026.06.005","type":"journal-article","created":{"date-parts":[[2026,6,12]],"date-time":"2026-06-12T11:16:30Z","timestamp":1781262990000},"page":"3740-3741","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":0,"title":["The self-replicating RNA platform expands to cancer immunotherapy with next-generation Eastern equine encephalitis virus vectors"],"prefix":"10.1016","volume":"34","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-0580-5209","authenticated-orcid":false,"given":"Lundstrom","family":"Kenneth","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.ymthe.2026.06.005_bib1","doi-asserted-by":"crossref","first-page":"181","DOI":"10.1080\/17425247.2024.2445675","article-title":"Self-amplifying RNA virus vectors for drug delivery","volume":"22","author":"Lundstrom","year":"2025","journal-title":"Expert Opin. Drug Deliv."},{"key":"10.1016\/j.ymthe.2026.06.005_bib2","doi-asserted-by":"crossref","first-page":"446","DOI":"10.1016\/j.ymthe.2017.11.017","article-title":"Self-amplifying RNA vaccines give equivalent protection against influenza to mRNA vaccines but at much lower doses","volume":"26","author":"Vogel","year":"2018","journal-title":"Mol. Ther."},{"key":"10.1016\/j.ymthe.2026.06.005_bib3","doi-asserted-by":"crossref","first-page":"1822","DOI":"10.1016\/j.cell.2024.03.018","article-title":"Self-amplifying RNA COVID-19 vaccine","volume":"187","author":"Wayne","year":"2024","journal-title":"Cell"},{"key":"10.1016\/j.ymthe.2026.06.005_bib4","doi-asserted-by":"crossref","first-page":"456","DOI":"10.1038\/s41467-025-55843-9","article-title":"Safety and immunogenicity of an optimized self-replicating RNA platform for low dose or single dose vaccine applications: a randomized, open label Phase I study in healthy volunteers","volume":"16","author":"Maine","year":"2025","journal-title":"Nat. Commun."},{"key":"10.1016\/j.ymthe.2026.06.005_bib5","doi-asserted-by":"crossref","first-page":"803","DOI":"10.1038\/s41417-023-00587-1","article-title":"Clinical trials of self-replicating RNA-based cancer vaccines","volume":"30","author":"Morse","year":"2023","journal-title":"Cancer Gene Ther."},{"key":"10.1016\/j.ymthe.2026.06.005_bib6","doi-asserted-by":"crossref","first-page":"4121","DOI":"10.1016\/j.ymthe.2026.03.026","article-title":"Enhanced Efficacy of a Next-Generation EEEV Self-Replicating RNA Platform for Combination Cancer Immunotherapies","volume":"34","author":"Miyake-Stoner","year":"2026","journal-title":"Mol. Ther."},{"key":"10.1016\/j.ymthe.2026.06.005_bib7","doi-asserted-by":"crossref","DOI":"10.1126\/scitranslmed.abc7804","article-title":"Local delivery of mRNA-encoded cytokines promotes antitumor immunity and tumor eradication across multiple preclinical tumor models","volume":"13","author":"Hotz","year":"2021","journal-title":"Sci. Transl. Med."},{"key":"10.1016\/j.ymthe.2026.06.005_bib8","doi-asserted-by":"crossref","first-page":"2573","DOI":"10.2147\/CMAR.S173193","article-title":"Clinical value of circulating ESR1 mutations for patients with metastatic breast cancer: a meta-analysis","volume":"10","author":"Zhang","year":"2018","journal-title":"Cancer Manag. Res."},{"key":"10.1016\/j.ymthe.2026.06.005_bib9","doi-asserted-by":"crossref","first-page":"827","DOI":"10.1084\/jem.170.3.827","article-title":"Identification and purification of natural killer cell stimulatory factor (NKSF), a cytokine with multiple biologic effects on human lymphocytes","volume":"170","author":"Kobayashi","year":"1989","journal-title":"J. Exp. Med."},{"key":"10.1016\/j.ymthe.2026.06.005_bib10","doi-asserted-by":"crossref","first-page":"882","DOI":"10.1038\/s43018-020-0095-6","article-title":"Multifunctional oncolytic nanoparticles deliver self-replicating IL-12 RNA to eliminate established tumors and prime systemic immunity","volume":"1","author":"Li","year":"2020","journal-title":"Nat. Cancer"},{"key":"10.1016\/j.ymthe.2026.06.005_bib11","doi-asserted-by":"crossref","first-page":"387","DOI":"10.1016\/j.omtn.2022.07.020","article-title":"Intratumoral electroporation of a self-amplifying RNA expressing IL-12 induces antitumor effects in mouse models of cancer","volume":"29","author":"Silva-Pilipich","year":"2022","journal-title":"Mol. Ther. Nucleic Acids"},{"key":"10.1016\/j.ymthe.2026.06.005_bib12","doi-asserted-by":"crossref","first-page":"114","DOI":"10.3389\/fphys.2014.00114","article-title":"The role IL-1 in tumor-mediated angiogenesis","volume":"5","author":"Voronov","year":"2014","journal-title":"Front. Physiol."},{"key":"10.1016\/j.ymthe.2026.06.005_bib13","doi-asserted-by":"crossref","first-page":"119","DOI":"10.1016\/j.ymthe.2019.09.009","article-title":"A trans-amplifying RNA vaccine strategy for induction of potent protective immunity","volume":"28","author":"Beissert","year":"2020","journal-title":"Mol. Ther."}],"container-title":["Molecular Therapy"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S152500162600482X?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S152500162600482X?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2026,7,1]],"date-time":"2026-07-01T21:01:25Z","timestamp":1782939685000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S152500162600482X"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,7]]},"references-count":13,"journal-issue":{"issue":"7","published-print":{"date-parts":[[2026,7]]}},"alternative-id":["S152500162600482X"],"URL":"https:\/\/doi.org\/10.1016\/j.ymthe.2026.06.005","relation":{},"ISSN":["1525-0016"],"issn-type":[{"value":"1525-0016","type":"print"}],"subject":[],"published":{"date-parts":[[2026,7]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"The self-replicating RNA platform expands to cancer immunotherapy with next-generation Eastern equine encephalitis virus vectors","name":"articletitle","label":"Article Title"},{"value":"Molecular Therapy","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.ymthe.2026.06.005","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"https:\/\/doi.org\/10.1016\/j.ymthe.2026.03.026","name":"associatedlink","label":"CrossRef DOI link to the associated document"},{"value":"simple-article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2026 The American Society of Gene and Cell Therapy. Published by Elsevier Inc. All rights are reserved, including those for text and data mining, AI training, and similar technologies.","name":"copyright","label":"Copyright"}]}}